Allarity Therapeutics, Inc. (ALLR) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Allarity Therapeutics, Inc. (ALLR) Healthcare & Pipeline Overview

Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company leveraging its drug response predictor technology to develop personalized oncology therapeutics. The company's pipeline includes multiple drug candidates in Phase 2 clinical trials targeting various cancers, positioning it within the competitive biotechnology sector focused on precision medicine.

What Is the Investment Thesis for ALLR?

Allarity Therapeutics operates in the high-risk, high-reward biotechnology sector, with a focus on personalized oncology treatments. The company's drug response predictor technology aims to de-risk drug development by identifying patients most likely to respond to specific therapies. Key value drivers include the successful completion of Phase 2 clinical trials for its lead drug candidates, particularly Stenoparib for ovarian cancer and LiPlaCis for metastatic breast cancer. Positive clinical data and subsequent regulatory approvals could significantly increase the company's valuation. However, the company's small market capitalization ($19.4M) and negative profit margin (-3509.7%) highlight the financial risks associated with investing in a clinical-stage biopharmaceutical company. Upcoming data readouts from ongoing clinical trials represent key catalysts, while potential setbacks in clinical development or regulatory hurdles pose significant risks.

Based on FMP financials and quantitative analysis

ALLR Key Highlights

Market capitalization of $19.4M reflects its status as a small-cap biotechnology company.

• Gross margin of 100.0% indicates efficient cost management in its operations.
• Profit margin of -3509.7% highlights the significant expenses associated with clinical-stage drug development.
• Beta of 0.20 suggests lower volatility compared to the overall market.
• No dividend yield reflects the company's focus on reinvesting earnings into research and development.

Who Are ALLR's Competitors?

ALLR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are ALLR's Key Strengths?

Proprietary drug response predictor technology.

• Pipeline of drug candidates in Phase 2 clinical trials.
• Focus on personalized medicine.
• Experienced management team.

What Are ALLR's Weaknesses?

Limited financial resources.

• Small market capitalization.
• Dependence on successful clinical trial outcomes.
• Negative profit margin.

What Could Drive ALLR Stock Higher?

Data readouts from Phase 2 clinical trials for Stenoparib in ovarian cancer (2026-2027).

• Data readouts from Phase 2 clinical trials for LiPlaCis in metastatic breast cancer (2026-2027).
• Data readouts from Phase 2 clinical trials for 2X-111 in metastatic breast cancer and glioblastoma multiforme (2026-2027).
• Potential strategic partnerships with pharmaceutical companies.
• Expansion of the company's companion diagnostic platform.

What Are the Key Risks for ALLR?

Financial-distress signal — its Altman Z-Score of -6.53 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for its drug candidates.
• Regulatory delays or rejections.
• Competition from larger pharmaceutical companies.
• Difficulty securing funding.
• Intellectual property disputes.

What Are the Growth Opportunities for ALLR?

• Expansion of Companion Diagnostic Platform: Allarity has the opportunity to expand the application of its drug response predictor technology to other therapeutic areas beyond oncology. This could involve partnering with pharmaceutical companies to develop companion diagnostics for their existing drug candidates or creating new diagnostic tests for emerging therapies. The market for companion diagnostics is projected to reach $8.6 billion by 2027, driven by the increasing adoption of personalized medicine. Timeline: Ongoing.
• Strategic Partnerships and Collaborations: Allarity can pursue strategic partnerships with larger pharmaceutical companies to co-develop and commercialize its drug candidates. These collaborations can provide access to funding, expertise, and established distribution networks. The pharmaceutical industry is increasingly relying on partnerships to access innovative technologies and expand their product pipelines. Timeline: Ongoing.
• Advancement of Pipeline Candidates: The successful completion of Phase 2 clinical trials for Stenoparib, LiPlaCis, and 2X-111 represents a significant growth opportunity for Allarity. Positive clinical data could lead to regulatory approvals and commercialization, generating substantial revenue streams. The market for ovarian cancer therapeutics is projected to reach $4.9 billion by 2028. Timeline: Upcoming data readouts in 2026-2027.
• Geographic Expansion: Allarity can explore opportunities to expand its operations into new geographic markets, particularly in Europe and Asia. These regions offer significant growth potential due to their large populations and increasing healthcare spending. The global oncology therapeutics market is expected to reach $286 billion by 2028, with Asia-Pacific being the fastest-growing region. Timeline: 2027-2028.
• Acquisition or Licensing of New Assets: Allarity can acquire or license new drug candidates or technologies to expand its pipeline and diversify its portfolio. This could involve acquiring assets from other biotechnology companies or licensing technologies from academic institutions. The market for biotechnology licensing deals is robust, with numerous opportunities to acquire promising assets. Timeline: Ongoing.

What Are ALLR's Competitive Advantages?

• Proprietary drug response predictor technology.
• Pipeline of drug candidates in Phase 2 clinical trials.
• Focus on personalized medicine and companion diagnostics.
• Intellectual property protection for its drug candidates and technologies.

What Does ALLR Do?

Allarity Therapeutics, Inc., founded in 2004 and headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company dedicated to developing oncology therapeutics. The company's core strategy revolves around utilizing drug-specific companion diagnostics, generated by its proprietary drug response predictor technology, to personalize cancer treatment. This approach aims to improve patient outcomes by identifying individuals most likely to respond to specific therapies. Allarity's pipeline features several drug candidates in various stages of clinical development. Key assets include Stenoparib, a poly-ADP-ribose polymerase inhibitor currently in Phase 2 clinical trials for ovarian cancer. Dovitinib, a pan-tyrosine kinase inhibitor, is being developed for the treatment of renal cell carcinoma. Additionally, the company is advancing IXEMPRA, a microtubule inhibitor targeting metastatic breast cancer. LiPlaCis, a liposomal formulation of cisplatin, is in Phase 2 trials for metastatic breast cancer, and 2X-111, a liposomal formulation of doxorubicin, is also in Phase 2 trials for metastatic breast cancer and glioblastoma multiforme. Allarity's focus on personalized medicine and its diverse pipeline of oncology therapeutics positions it as a player in the biotechnology industry.

What Products and Services Does ALLR Offer?

• Develop oncology therapeutics.
• Utilize drug-specific companion diagnostics.
• Employ drug response predictor technology.
• Conduct Phase 2 clinical trials for various cancer treatments.
• Develop poly-ADP-ribose polymerase inhibitors.
• Develop pan-tyrosine kinase inhibitors.
• Create liposomal formulations of chemotherapy drugs.

How Does ALLR Make Money?

• Develop and commercialize oncology therapeutics.
• Generate revenue through licensing agreements and partnerships.
• Focus on personalized medicine using companion diagnostics.
• Advance drug candidates through clinical trials to regulatory approval.

What Industry Does ALLR Operate In?

Allarity Therapeutics operates within the biotechnology industry, a sector characterized by intense competition, high research and development costs, and lengthy regulatory approval processes. The industry is driven by innovation and the pursuit of novel therapies for unmet medical needs. The market for oncology therapeutics is substantial and growing, fueled by an aging population and increasing cancer incidence rates. Allarity's focus on personalized medicine aligns with the industry trend towards targeted therapies and precision diagnostics. Competitors include both large pharmaceutical companies with established oncology franchises and smaller biotechnology firms developing innovative cancer treatments. The company's success depends on its ability to successfully navigate the clinical development and regulatory pathways, secure funding, and differentiate its products in a crowded market.

Who Are ALLR's Key Customers?

• Patients with cancer.
• Oncologists and other healthcare professionals.
• Hospitals and cancer treatment centers.
• Pharmaceutical companies (potential partners).

The most recent 10 insider filings for Allarity Therapeutics, Inc. break down as 2 sales and 8 purchases. On net that is roughly 816K shares acquired (about $23K) — insiders putting money in tends to read as conviction.

Quarterly Financial Performance: Allarity Therapeutics, Inc.

Revenue for Allarity Therapeutics, Inc. came in at $25K during Q1 FY2026, a 92.2% contraction versus the preceding quarter. The company recorded a net loss of $2.8M, with diluted EPS of $-0.17.

ALLR Valuation & Market Position

With a $19.4M market cap, Allarity Therapeutics, Inc. sits in the micro-cap segment of the market. Relative to its peer group, ALLR's quantitative score of 19/100 is below the peer average of 77/100.

Key Financial Metrics

Return on assets is -32.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -64.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.23 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -43.0%, the inverse of the P/E and a quick read on earnings relative to price.

Allarity Therapeutics, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -6.53 places it in the distress zone, a signal of elevated financial risk.

Allarity Therapeutics, Inc. has beaten Wall Street's EPS estimate in 7 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 111.1% below estimates on average.

Company Profile

Allarity Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Tarpon Springs, US. The company is led by CEO Thomas H. Jensen. ALLR has traded publicly since 2021.

ALLR Financials

ALLR Latest News

ALLR Analyst Consensus

ALLR MoonshotScore

What Investors Ask About Allarity Therapeutics, Inc. (ALLR) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources